[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601923":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":26,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":84,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Steroids Group","EXPERIMENTAL","Methylprednisolone sodium succinate (80 mg\u002Fday) on days 1-3 post-surgery, followed by prednisone acetate (20 mg\u002Fday) on days 4-10.",[13],"Drug: Steroids therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","Methylprednisolone sodium succinate placebo on days 1-3 post-surgery, followed by prednisone acetate placebo on days 4-10.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Steroids therapy","Methylprednisolone sodium succinate 80 mg powder dissolved in 100 mL of sodium chloride solution (intravenous infusion, once daily) from the day of surgery to day 3, followed by 20 mg of prednisone acetate (oral intake, once daily) from day 4 to day 10.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Methylprednisolone sodium succinate placebo powder dissolved in 100 mL of sodium chloride solution (intravenous infusion, once daily) from the day of surgery to day 3, followed by prednisone acetate placebo (oral intake, once daily) from day 4 to day 10.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Wang Jia, PhD","CONTACT","8615510033866","jwttyy@126.com",[38],{"facility":5,"status":26,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Beijing","Beijing Municipality","100070","China","CN",{"type":45,"coordinates":46},"Point",[47,48],116.39723,39.9075,{"lat":48,"lon":47},[51,52],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"name":33,"role":53,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Wang Jia","Professor of Beijing Tiantan Hospital, Capital Medical University","100601923","phase-3-steroids-for-facial-nerve-function-protection-in-post-surgical-vestibular-schwannoma-patients-100601923",false,"NCT07116811","Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients","The Effect of Steroids Treatment for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients (SAF-NRVS): a Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Trial","SAF-NRVS","Inclusion Criteria:\n\n1. Age between 18 and 60 years\n2. Diagnosed with untreated unilateral vestibular schwannoma\n3. No facial palsy before surgery (House-Brackmann grade I)\n4. Intraoperative neurophysiological monitoring confirms good facial nerve function preservation, defined as: a）Post-tumor resection, evoked compound muscle action potential amplitude \\>420 μV under 0.05 mA stimulation；and b）The amplitude is \\>60% of baseline value measured before dural opening\n5. Signed informed consent\n\nExclusion Criteria:\n\n1. Contraindications for craniotomy\n2. Patients requiring corticosteroids during the perioperative period, or with known corticosteroid contraindications\n3. Patients or first-degree relatives with a confirmed diagnosis of neurofibromatosis type 2 (NF2)\n4. Karnofsky Performance Status (KPS) score \\\u003C90 before disease onset\n5. Pregnant or planning to become pregnant during the study period\n6. Participation in other interventional clinical trials\n7. Judged unsuitable by the investigators","ALL","18 Years","60 Years",{"count":69,"type":70},364,"ESTIMATED","INTERVENTIONAL",[73],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of steroids treatment compared with placebo in preserving facial nerve function after craniotomy in patients with vestibular schwannoma who have not received preoperative treatment and have good intraoperative facial nerve function.",[76,77],"Vestibular Schwannoma","Facial Nerve Paralysis",[79,80,81,82,83],"Steroids","Facial Nerve Function","Intraoperative Neurophysiological Monitoring","Randomized Controlled Trial","Facial Palsy","NOT_YET_RECRUITING","2025-08-07",{"date":87,"type":88},"2025-08-12","ACTUAL",{"date":90,"type":70},"2025-09-01",{"date":92,"type":70},"2027-09-30",{"name":5,"class":6},1]